Literature DB >> 12944021

Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.

Kelley A Gordon1, Douglas J Biedenbach, Ronald N Jones.   

Abstract

The SENTRY Antimicrobial Surveillance Program has been monitoring the activity of commonly prescribed and novel antimicrobial agents on a global scale from 1997 to the present. Specific objectives have documented the key resistance rates among pathogens from both patients hospitalized with pneumonia and those diagnosed with community-acquired pneumonia. Hemophilus influenzae and Streptococcus pneumoniae are common pathogens in both of these patient populations and the susceptibility profiles for these two species were compared to distinguish potential differences that may be evident in North American surveillance (1997-2001). A total of 6,515 isolates of S. pneumoniae and 6,726 H. influenzae strains were tested using reference broth microdilution methods at a monitoring center. Ampicillin resistance was approximately 25% among H. influenzae isolates and did not significantly differ between strains from community-acquired infections or hospitalized patients. beta-lactamase-negative ampicillin resistant strains and fluoroquinolone refractory strains were rare (0.3 and </= 0.2%, respectively) and the former only detected among hospitalized patients. Macrolide-resistant H. influenzae was most prevalent in hospitalized patients with pneumonia (24.4% for clarithromycin). In contrast, H. influenzae isolates from community-acquired infections were less susceptible (78.6-81.7%) to trimethoprim/sulfamethoxazole, but very susceptible to fluoroquinolones (99.9-100.0%). The community-acquired S. pneumoniae isolates were generally more resistant to penicillin (16.7%) and other beta-lactams compared to those from hospitalized patients (12.1%), and were also much more resistant to trimethoprim/sulfamethoxazole (25.0%) compared to inpatient isolates (6.7%). In contrast, isolates with reduced fluoroquinolone susceptibility or resistance were more common among hospitalized patients (ciprofloxacin resistance at 4.0%) and increased over the five monitored years. It is evident from this longitudinal study that some antimicrobial agents are becoming less efficacious against common respiratory tract pathogens depending on the clinical setting and surveillance of resistance appears to be a prudent practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12944021     DOI: 10.1016/s0732-8893(03)00087-7

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  14 in total

Review 1.  Amoxicillin/clavulanic acid 2000mg/125mg extended release (XR): a review of its use in the treatment of respiratory tract infections in adults.

Authors:  Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study.

Authors:  M M van der Eerden; F Vlaspolder; C S de Graaff; T Groot; W Bronsveld; H M Jansen; W G Boersma
Journal:  Thorax       Date:  2005-08       Impact factor: 9.139

Review 3.  Beginning antibiotics for acute rhinosinusitis and choosing the right treatment.

Authors:  Ellen R Wald
Journal:  Clin Rev Allergy Immunol       Date:  2006-06       Impact factor: 8.667

4.  Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia.

Authors:  M M van der Eerden; F Vlaspolder; C S de Graaff; T Groot; H M Jansen; W G Boersma
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-04       Impact factor: 3.267

5.  Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients.

Authors:  H H Huang; Y Y Zhang; Q Y Xiu; X Zhou; S G Huang; Q Lu; D M Wang; F Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-06       Impact factor: 3.267

6.  Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.

Authors:  Ralf René Reinert; Susanne Reinert; Mark van der Linden; Murat Y Cil; Adnan Al-Lahham; Peter Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

Review 7.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe.

Authors:  Ralf René Reinert; Adrian Ringelstein; Mark van der Linden; Murat Yücel Cil; Adnan Al-Lahham; Franz-Josef Schmitz
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  Time-to-Recovery from Severe Pneumonia and Its Determinants Among Children Under-Five Admitted to University of Gondar Comprehensive Specialized Hospital in Ethiopia: A Retrospective Follow-Up Study; 2015-2020.

Authors:  Tigabnesh Assfaw; Chalachew Yenew; Kassahun Alemu; Wullo Sisay; Teshome Geletaw
Journal:  Pediatric Health Med Ther       Date:  2021-04-21

10.  Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.

Authors:  Cristina Tanaseanu; Slobodan Milutinovic; Petre I Calistru; Janos Strausz; Marius Zolubas; Valeriy Chernyak; Nathalie Dartois; Nathalie Castaing; Hassan Gandjini; C Angel Cooper
Journal:  BMC Pulm Med       Date:  2009-09-09       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.